地尔硫(艹卓)对冠脉内支架术后胸痛患者的疗效

目的评价地尔硫对冠脉内支架术后胸痛患者的近期疗效和远期再狭窄的影响。方法冠脉内支架术后胸痛患者251例,其中地尔硫治疗189例(75.3%),其余62例(24.7%)未接受地尔硫治疗。比较两组随访期严重心脏事件(死亡、心肌梗死和重复靶血管再通治疗)和再狭窄率。结果在中位数128d的随访期内,严重心脏事件在地尔硫组为4.8%,非地尔硫组为12.9%(P=0.039)。42.6%患者于1年内行血管造影随访,地尔硫组的再狭窄发生率显著降低(11.5%和29.2%,P=0.05)。结论地尔硫对冠脉内支架术后胸痛患者有一定疗效。

Effects of diltiazem on angiographic and clinical outcomes in patients with chest pain following coronary stenting

Objective To evaluate the effects of diltiazem on angiographic and clinical outcomes in patients with postprocedural chest pain after coronary stenting. Methods Two hundred and fifty-one patients with postprocedural chest pain were divided into two groups: diltiazem group (n = 189) and control group (n = 62). The outcomes of the two groups were compared according to the following two points. The first point was the major adverse cardiac events, including mortality, nonfatal infarction and target lesion revascularization. The second point was restenosis during the follow-up period. Results By the median of 128 days, the severe composite clinical events reached 4.8% in the diltiazem group and at 12.9% in the control group (P = 0.039). Repeated angiography was performed in 42.6% of these patients within one-year showing 11.5% restenosis in the diltiazem group and 29.2% in the control group (P = 0.05). Conclusions In patients with postprocedural chest pain after coronary stenting, oral diltiazem contributes a favorable outcome. (J Intervent Radiol, 2006, 15: 261-263)